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Introduction
Integrins are af amily of heterodimeric cell surface receptors that mediate cell-extracellular matrix and cell-cell interactions.
[1] Integrin-mediated adhesion is critical in multiple phases of development and maintenance of tissue physiology. Conversely,a berrant integrin function that can arise because of inappropriate levels of activationi si mplicated in many diseases, including cancer,t hrombosis, and immune system disorders.
[2] In particular,r ecent studies provide evidenceo ft he importance of pairs andw ider combinationso fR GD-bindingi ntegrins in angiogenesis andc ancer,a nd suggest the development of dual and multi-integrin antagonists to efficiently target these processes. [3] Among tumor-associatedi ntegrins from the RGD-binding subfamily, a 5 b 1 along with a V b 3 and other a V integrins are highly expressed on aw ide range of tumors and surroundingv asculature, where they are correlated with disease progression and poor prognosis. These integrins recognize the RGD sequence in endogenous ligands(e.g. fibronectin,v itronectin) across their extracellular a/b subunit interface containingt he metal-ion-dependent adhesion site (MIDAS). [4] The context of the ligand RGD sequence (flanking residues,t hree dimensionalp resentation)a nd different features of the integrin binding pocket determine the recognition specificity. [5] The most used strategy to inhibiti ntegrin functionc onsists of blockinge ndogenous ligand binding by small-molecule integrin antagonists designed around the epitope of the natural ligands: the RGD motif. Unfortunately,l inear RGD-containing peptidess uffer from low affinity and specificity,a so ne factor that affects integrin affinity and specificity for RGD ligands is aw ell-defined conformation of the ligand. This drawback has been circumvented by the use of cyclic peptidic and peptidomimeticl igands, and al arge number of such ligands have been developed that target tumor-associated integrin heterodimers with high affinity and specificity and show potential as
The interaction of as mall library of cyclic DKP-RGDp eptidomimetics with a 5 b 1 integrin has been investigated by means of an integrated experimental and computational approach. Bioaffinity NMR techniques, includings aturation transfer difference (STD) and transferred NOESY,w ere appliedt ot he ligands in as uspension of intact MDA-MB-231b reast cancerc ells, in which integrin a 5 b 1 is highly expressed. The NMR data were compared with the docking calculations of the RGD ligands in the crystal structure of the a 5 b 1 binding site, and were integrated with competitive bindinga ssays to the purified a 5 b 1 integrin. Ligand binding epitopes involvep rotons of both the RGD moiety and the DKP scaffold, although the stereochemistry and the functionalization of the DKP scaffold as well as the macrocycle conformationd etermine ag reat variability in the interaction. The ligand showing the highest number of STD signals is also the mostp otent a 5 b 1 ligand of the series,d isplaying an anomolar IC 50 value.
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both antitumor anda nti-angiogenic agents. [3, 5, 6] Amongt hem, the cyclic pentapeptide cyclo[RGDf(N-Me)V] 1a (developed by Kessler and known as Cilengitide, Figure 1 ) hasr ecently failed aP hase III clinical trial for the treatment of glioblastoma and is currently undergoing other Phase II clinical trialsf or the treatment of several cancer types, administered either alone or in combination with othertherapeutic agents. [5, 7] In this context, we have recentlyr eported as mall library of cyclic RGD peptidomimetic integrin ligands, containing diketopiperazine (DKP) scaffolds, as dipeptidem imics capable of controlling the conformation of the tripeptide recognition motif, as well as differing in the configurationo ft he two DKP stereocenters and in the substitution at the DKP nitrogen atoms. [8] In particular, the RGD peptidomimetics 2-7 (Figure 1 ) derived from trans-DKP scaffolds( DKP2-DKP7) inhibited the bindingo f biotinylated vitronectin to a V b 3 integrin with low nanomolar IC 50 values. The molecular basis of this activity was rationalized in terms of preferred ligand conformationsf eaturing an extended arrangemento ft he RGD sequence, which are highly pre-organized for the interaction with integrin a V b 3 ,a sd emonstrated by dockings tudies and NMRe xperiments with a V b 3 -rich bladder cancercells. [9] Prompted by these resultsa nd by the perspective of targeting two key players in angiogenesis and canceri nt he RGDbinding integrin subfamily,weplanned to investigate the interaction of our cyclic RGD peptidomimetics with a 5 b 1 integrin by exploiting the same integrated computational and experimental approach applied in the study of a V b 3 integrin.
Recently reportedX -ray structureso fd ifferent a 5 b 1 integrin headpiece fragments, both in the absence and presence of linear or cyclic RGD ligands, providea ni mportant starting point for developinga nu nderstanding of the interaction with small-molecule ligands.
[10] Despite some differencesi nt he overall a 5 b 1 headpiece structure, the cyclic peptide RGD moiety adopted ab ound extended conformation very similar to the linear RGD peptides and to the cyclic pentapeptide 1a (Cilengitide)-bound to a V b 3 integrin. [11] Indeed, the X-ray structures of a V b 3 and a 5 b 1 complexed with RGD ligandsr eveala n identicala tomicb asis for the interaction:R GD binds at the junction of the a and b subunits,t he Arg residue fitting into ac left in the a subunit, and the Asp coordinating ac ation in the b subunit. In particular,t he RGD tripeptide adoptsahighly extended conformation( displaying ad istance of about 9 between the Cb atoms of Asp and Arg) acrosst he a V b 3 and a 5 b 1 integrin subunit interface with the carboxylic and guanidine groups acting as an electrostatic clamp, respectively,o nap ositively charged metal ion of the b subunit (MIDAS) and on several a subunit specific acid residues.
The properties of integrinse mbedded into cell membranes differ from those of purified receptors, so ap ure in vitro or in silico system may not fully recapitulate the complexity of integrin-mediated recognition. In this regard, NMR spectroscopy is ap owerful tool for the study of small molecule-biomolecule complexes. [12] In addition, bioaffinity NMR experiments can be conducted on small ligandsd irectly in the presence of intact cells, allowing foradetailed investigation into the binding process very close to physiological conditions. [9, 13] Accordingly,t oi dentify the molecular details of the interaction of our cyclic RGD peptidomimetics with a 5 b 1 integrin, we appliedb ioaffinity NMR techniques, including saturation transfer difference( STD) and transferred NOESY (tr-NOESY), to ligands in as uspension of MDA-MB-231b reast cancer cells, in which integrin a 5 b 1 is highly expressed. The NMR data were integrated with the dockingc alculations of the RGD ligandsi n the crystal structure of the a 5 b 1 binding site, thus affording an improved understanding of ligand-integrin interactions. Herein, we report af ull account of our investigationst hat have been completed with competitive bindinga ssays to the purified a 5 b 1 receptor.
Results and Discussion

Integrin Receptor Competitive Binding Assays
The cyclic RGD peptidomimetics 2-7 were examined in vitro for their ability to competew ith biotinylated fibronectin for binding to the purified a 5 b 1 receptor.S creening assays were performed by incubating the immobilizedi ntegrin receptor with variousc oncentrations( 10 À12 -10 À4 m)o ft he RGD ligands in the presence of biotinylated fibronectin (1 mgml À1 ), and measuring the bound fibronectin in the presenceo ft he competitivel igands. The ability of the peptidomimetics 2-7 to inhibit the binding of biotinylated fibronectin to a 5 b 1 integrin (expressed as the ligand concentration required for50% inhibition) was compared with that of reference compounds 1a (Cilengitide) and 1b [cyclo(RGDfV), Figure 1 ] and with the corre- (Table 1) .
All of the ligands showed binding affinities for a 5 b 1 lower than those for a v b 3 ,d isplaying as electivity ratio (IC 50 a 5 b 1 /IC 50 a v b 3 )r anging from about 35 (compound 6)t oa pproximately 500 (compound 2). The reference compounds 1a and 1b confirmed this trend, exhibiting binding affinitiesf or a 5 b 1 about 25-50 times lower than those for a v b 3 .O ne potential explanation for this behavior (vide infra) might be the differencesb etween the bindings ites of the two receptor subtypes that can weaken the electrostatic clamp and other specific interactions. Amongt he peptidomimetics tested, compound 7 showedt he highest affinity toward a 5 b 1 integrin, inhibiting the bindingo f biotinylated fibronectin to a 5 b 1 with an IC 50 value of 25.7 nm. Interestingly,t his ligand was also the most potent a v b 3 ligand of the series, displaying as ub-nanomolar IC 50 value. Compared to the corresponding a v b 3 binding affinities, the a 5 b 1 IC 50 values showed am ore pronouncedd ependence on the structure of the DKP scaffold, ranging from nanomolar to micromolar concentrations.
DockingModels of a 5 b 1 Integrin
Computational models for the interaction of RGD peptidomimetic ligands 2-7 with the a 5 b 1 integrin wereb uilt by means of docking calculations using the Glide program (version 5.7) of the Schrodinger suite. [14] Twom odelsw ere developed (see the Experimental Section for details), one startingf rom the Xray structure of af ive-domain a 5 b 1 headpiece fragment bound to the allosterica nti-b 1 inhibitory antibody SG/19 and in complex with al inear RGD peptide (3VI4.pdb), [10b] and the other one using the most recent high-resolution crystal structure of af our-domain a 5 b 1 headpiece fragment in complex with the disulfide-bonded cyclic peptide ACRGDGWCG (4WK4.pdb). [10a] As noted by the authorso fR ef. [10a] ,t he overall a 5 b 1 headpiece structure is very similar in both complexes and approximated to an integrin state that is intermediate between closed (low affinity) and open (high affinity). Moreover,t he cyclic peptide RGD moiety adopts ab ound conformation and ab inding mode very similart ot hose of the linear RGD peptide. In both X-ray complexes,t he RGD motif binds at the junction of the a 5 and b 1 subunits,a dopting ah ighly extended conformation across the integrin subunit interface. The Arg and Asp side chainse xtendi no pposite directions, acting as an electrostatic clamp and interacting with the negativelyc harged Asp227 side chain of a 5 subunit and the b 1 MIDAS cation, respectively. Further stabilizing hydrogen bondso ccur between the ligand Arg guanidine group and a 5 Gln221 side chain, the ligand Asp carboxylic group and b 1 Asn224, Tyr133b ackbone amide and Ser132s ide chain, and between the ligand Asp backbone amide and the backbonec arbonyl of b 1 Leu225.I na ddition, the cyclic peptideT rp sidec hain forms aT -shaped interaction with the a 5 Trp157 side chain.
Although the RGD binding mode found in a 5 b 1 integrin recapitulates the RGD interaction with b 3 integrins, differences between a 5 b 1 and a V b 3 integrin binding pockets can affect the ligand recognition,a ss hown by competitive binding assays (Table 1) . For instance, the mutation of a V Asp150 into a 5 Ala159p roduces al ess acidic region, whereas the mutation of Arg214a nd Arg216 (b 3 )i nto the hydrophobic residues Gly223 and Leu225 (b 1 )b oth expands the site and reduces the polar character of the region.O wing to the different physicochemical features of binding sites, the ligandsc ould interact less strongly with a 5 b 1 and revealag reater mobility within this receptor site compared to a V b 3 .
In all of the calculations, the X-ray binding mode of the RGD motif with the a 5 b 1 integrin was taken as ar eference model for the analysis of the dockingr esults in terms of ligand-protein interactions (see Figure S1 ). According to the similarity between the crystal structures of a 5 b 1 (3VI4 and 4WK4), comparable results for the docking of ligands 2-7 in the two a 5 b 1 integrin modelswere obtained.
NMR Analysis
The molecular detailso ft he interaction between our cyclic RGD peptidomimetics and a 5 b 1 integrin were investigated by applying bioaffinity NMR techniquestothe ligandsinasuspension of intact MDA-MB-231 breast cancer cells, in which the integrin a 5 b 1 is highly expressed (a 5 b 1 /a V b 3 expression ratio = 7.1, ratio of mean fluorescencei ntensity determined by flow cytometry). [15] The NMR analysiso ft he interaction was performed by saturation transfer difference (STD) and transferred NOESY (tr-NOESY) that focuso nt he NMR signals of the ligand and utilize NOE effects between the protein and the ligand. In particular, STD experiments permitted the identification of the epitope, pinpointing the interaction betweenp arts of each ligand and the receptor,w hereast r-NOESY data provided information on the bioactivec onformation.
The conformation of ligands 2-7 in the presence of intact MDA-MB-231c ells was detected by tr-NOESY experiments performed at2 83 Ki nn on-deuterated phosphate buffer at pH 7.2. Undert hese experimental conditions, compounds 3, 4, 5,a nd 7 confirmed the free-state conformationalb ehavior (summar- ized in the Supporting Information), [8c] displaying NOE contacts in the bound state very similar to those in the free state. In particular,l igands 3 and 5 show,i nt he respectivet r-NOESY spectra,across peak between NH Arg ÀNH Gly ,w hich is indicative of ap seudo-b-turn motif at DKP-Arg stabilized by ah ydrogen bond between NH Gly and C(5) = O( referred to as at ypeIII Hbondingp attern, [16] Figure 2) .
Also, the conformation of ligand 2 in the presence of the cell suspension can be re-conducted to the type III geometry observedi nt he free state, although the significant NOE contact is absent in the tr-NOESY spectrum. Indeed, the similarity of all other NOE contacts in the free and bound state does not suggest significant differences between the corresponding conformations.
Conversely,l igands 4, 6,a nd 7 were shown in the free state to adopt ac onformation characterized by a b-turn motif at Gly-Asp stabilized by ah ydrogen bond between DKPÀNH 10 and ArgÀC=O( referredt oa satype IH -bonding pattern, Figure 3) , [16] and by the NH 10 ÀNH Asp NOE contact (at least in compounds 6 and 7). Their tr-NOESY spectra revealed high similarity to the free-state spectra, confirming the presence of the type Ic onformation in the interaction with a 5 b 1 integrin. Interestingly,o nly the cross peak NH 10 ÀNH Asp is evident in the tr-NOESY spectrum of compound 6 (Figure3), suggesting the selection of the type Ic onformation in the bound state between the two main geometries detected in the free state (described in the Supporting Information).
[8c] Remarkably,t he ligands adopting the type Ic onformation in the bound state (compounds 4, 6 and 7)s howedt he best binding affinities to the a 5 b 1 receptor among the cyclic RGD peptidomimetics (lowest IC 50 values in Table 1) .
To provide information,a ta tomic level, on the ligand interactions with protein residues, one-dimensional STD experiments of the compounds 2-7 in the presenceo fM DA-MB-231 cell suspension were performed. As control experiments,t he STD spectra of aR GD ligand withoutc ells and of an on-RGD compound (e.g. mannose) in the presence of cells were recorded. In both cases, no signals were observed. The protons of compounds 2-7,w hich exhibit as ignal in the STD spectra and This scheme highlightsh ow all compounds have points of contact with the a 5 b 1 receptor.T ransfer signals generally require ad istance from the receptor of less than 5 ,a nd the smaller the distance compared with other residues in the ligand,t he strongert he transfer signal. Therefore, the degree of saturation of individuall igand protons( expressed as absolute-STD percent) reflects their proximity to the target surface. The absolute STD values of all ligands (see Ta ble S7 of the Supporting Information) can be compared by considering the similar natureo ft he compounds, the equivalence in concentration and in the ratio ligand to protein of the samples. To facilitate the interpretation of NMR data, absolute STD percent values are transformed into relative STD %v alues (see Table S7 ) for each molecule on the basis of the strongest signal. The relative STD %a re grouped into fivei ntensity ranges,a ss hown in Figure 4 ( black = 100 %, green > 70 %, 50 < red < 70 %, 30 < orange < 50 %, yellow < 30 %).
Af irst analysiso ft he STD data indicates the great variability of the interactions:e ach ligand binds the receptor site with ad ifferent epitope. Indeed, the STD spectra of ligands 2-7 in the presence of cells differ for the number and intensityo ft he signals and for the typeo fp rotons involved in the interaction. This behavior underlines how the ligand stereochemistry and functionalization at the DKP nitrogen atoms are decisive in the formation of the ligand-protein complex. The CH 2 -benzylic protons and DKP-H6 are not evaluated, because their chemical shifts are very close to the water signal.
However,all of the ligandsshare somecommonbinding features:t he aromatic and the guanidinic protons are in contact with the receptor,a lthoughw ith different STD percentages. Overall,w ithin the RGD motif, the arginine residue displays ah ighert ransfer signal than the aspartate residue, presumably because the aspartate interaction with the receptor is mediated by the coordination to am etal cation and, thus, compared with arginine, the aspartate protons could be more distant from the integrin. The STD NMR data were interpreted with the aid of docking calculations in the crystal structure of the a 5 b 1 binding site and an integrated discussion is reported below for each ligand.
Ligands Adopting the Type IBound Conformation
The STD spectrum of ligand 7 in the presence of MDA-MB-231 cell suspension is shown in Figure 5 .
With respectt ot he other library compounds, this ligand shows the highest number of protonsi nvolved in the interaction with an intensity greater than 50 %o fr elative STD. The largestS TD effects (greater than 70 %o fr elative STD) are observed for DKP-H9, DKP-H3 (protons of the scaffold) and the Figure 4 . Relative STD %v alues,g rouped in five intensity ranges for ligands 2-7 interacting with MDA-MB-231 cells (black = 100 %, green > 70 %, 50 < red < 70 %, 30 < orange < 50 %, yellow < 30 %). (Figure 4 , red balls). Additionally,t he signals of NH Gly and NH Asp overlap and it is difficult to assess their involvement in the binding process. Overall,t he interaction of 7 with the receptor site is strong and involves protons of both the RGD moiety and the DKP scaffold. Indeed, this compound appears to be the most potent ligand of the series by effectively inhibiting the binding of biotinylated fibronectin to the isolated a 5 b 1 integrin at nanomolar concentration (IC 50 = 25.7 AE 6.2 nm). Docking calculations starting from the type Ib ound conformation of compound 7 produced top-ranked binding modes,c onserving all the key interactions described for the RGD peptides in the Xray complexes (Figure 6a ).
In addition to the interactions of ligand guanidinium group with a 5 Asp227 (side-on) and Gln221 (head-on) side chains, and to the interactions of ligand carboxylate moiety with MIDAS and b 1 Asn224, Tyr133, Ser134 backbone amides, further stabilizing Hb onds occur betweent he ligand Asp backbone amide and the carbonyl of b 1 Leu225,a nd between the ligand Gly backbonec arbonyl andt he b 1 Ser227 side chain. Moreover,i na greement with the STD data, the two benzyl groups are in contact with b1s ubunit residues,o ne interacting with the aromatic side chain of Tyr133 and the other one pointingt owards ADMIDAS ion and some surroundingr esidues (Ser134, Asp259,A la342), and the protons DKP-H3 and DKP-H9oft he scaffold are close to the b1Ser134residue.
Compounds 4 and 6 feature the same benzyl substitution at the endocyclic nitrogen N-1 of the scaffold and the opposite configuration of the two DKP stereocenters( see Figure4) . Accordingly, the two side arms of the diketopiperazine scaffold show ad ifferent stereochemical orientation that could affect the interaction of the ligandsw ith the a 5 b 1 receptor site. In fact, even though, for both ligands, the largest STD effect involvest he aromatic protons (100 %relative STD), the STD spectra of 4 and 6 show some differences in intensity and assignment of the signals. Similarly to ligand 7,t he STD spectrum of compound 6 includes protons belonging to both the scaffold and the RGD moiety:N H4, DKP-H9, Ha Gly ,a nd the guanidine NH protons show comparable and notable STD intensities (48-63 %r elative STD, see Table S7 of the Supporting Information) and, consequently,a st he aromatic protons, can be considered lying close to the protein surface. This analysis nicely agrees with the ability of ligand 6 to inhibitt he bindingo fb iotinylated fibronectin to the isolated a 5 b 1 integrin at nanomolar concentration (IC 50 = 73.3 AE 3.7 nm). In agreement with the STD data and similarly to compound 7,d ocking calculations show that compound 6 binds to the a 5 b 1 receptor with the Asp carboxylate group coordinating the metal ion at the MIDAS and interacting with b 1 Asn224, Tyr133, Ser134 backbone amides, and the Arg guanidinium moiety establishing ab identate salt bridgew ith a 5 Asp227 and aHb ond with a 5 Gln221 (Figure 6b) . Moreover,t he benzylm oiety is in proximity to b 1 Ser227a nd a 5 Ser224, confirming the importance of the interaction of the aromatic group with the integrin bindingp ocket, whereas Ha Gly is in contact with the a 5 Phe187 side chain,a nd protons NH4 and DKP-H9o ft he scaffold are close to the b 1 Ser134r esidue. It is worth noting that, compared to ligand 7, compound 6 orientates the scaffold and the aromatic ring toward ad ifferentr egion of the receptors ite ( Figure 6 ). This binding mode affects the interaction of the whole ligand with the receptor and, as ac onsequence, could explain the lack of STD signals for some protons.
The STD spectrumo fc ompound 4 includes protons belonging to the DKP scaffold, the benzyl group, and the Arg residue, suggesting the close proximity of these moieties to the integrin surface. Comparedt o6,w eo bserve as ignificante nhancement of STD intensity for DKP-H7, the appearance of important signals for DKP-H3a nd NH Arg ,a nd the disappearance of the Ha Gly contact. Docking calculations show that compound 4 can fit into the a 5 b 1 receptor pocket with different energetically favorable orientations, mainly differing in the position of the aromatic group and, consequently,o ft he DKP scaffold and the cyclic peptide backbone (see Figure S5 ). The mobility of the ligand within the a 5 b 1 bindings ite revealed by docking poses is likely responsible of the non-optimal interaction pattern observed for the RGDs equence witht he MDA-MB-231c ells and In conclusion, for type Il igands 4, 6,a nd 7,t he aromatic groups display the major STD intensity.M oreover,t he interaction between the guanidiniumg roup and the integrin is present in all the compounds, whereas the RGD backbone and DKP scaffold protons contribute differently to the ligand epitope.
Ligands Adopting the Type III Bound Conformation
The ligandsa dopting the type III conformationi nt he bound state (compounds 2, 3,a nd 5)s howedt he lowest binding affinities to the a 5 b 1 receptor among the cyclic RGD peptidomimetics tested (highest IC 50 valuesi nT able 1, ranging from 532 AE 35 nm of 3 to 1647 AE 871 nm of 2). Nevertheless, clear peaks caused by magnetization transfer were observed in their STD spectra,r evealing different binding epitopes to a 5 b 1 -rich cancer cells, which share the aromatic andt he guanidinic protons, even thoughw ith variable intensities. In particular, the STD spectrumofcompound 2 (displaying the greatest variability in the competitive binding assay and the worst a 5 b 1 IC 50 ) shows many signals of low intensity,r elative to protons of both the scaffold and the RGD moiety,a nd only one signal (NH Guan )d isplaying an absolute STD percentage higher than 1% (TableS7o ft he Supporting Information). This behavior suggestst hat the most importantr ecognition takes place by means of the guanidinium group (100 %r elative STD) and that the cyclopeptidec onformationo fl igand 2 combined with its DKP configurationd oes not likely allow af avorable interaction of the other protons (e.g. the aromatic protons) with a 5 or b 1 residues.O nt he contrary,t he STD spectra of ligands 3 and 5 show 100 %r elativeS TD effects for the aromatic protons, indicating their close proximity to the integrin surface. Relative STD %v alues of notable intensity are displayed also by guanidine and scaffold protons of these ligands, supporting their ability to interact with a 5 b 1 -rich cancercells.
Docking calculations startingf rom the type III conformation into the a 5 b 1 model generated ligand binding modes that could explain the poor ability of compounds 2, 3,a nd 5 to competew ith biotinylated fibronectin for the binding to the purified a 5 b 1 integrin, while maintaining extended conformations and several interactions with the receptor site. In fact, docking results starting from type III conformationss howed both the classical RGD interaction pattern observed in X-ray complexes as well as alternative binding modes lacking the classical electrostatic clamp. This behaviori sw ell exemplified by docking poses of ligand 3,w hich adopts two main binding modes within the a 5 b 1 receptor site (Figure 7 ). In the best pose, representing binding mode A ( Figure 7a) , ligand 3 forms all the key crystallographic interactions, where the benzyl group is in contact with the side chains of b 1 Tyr133, Ser134, Asp259 and Glu320, and the NH 10 proton is closet ot he b 1 Ser134 residue. In the alternative binding mode B ( Figure 7b ), at less favorable docking scores, the guanidinium group loses the electrostatic interaction with the a 5 Asp227 side chain and forms ac ation-p interaction with the a 5 Trp157 aromatic ring and as alt bridge with the a 5 Glu126 side chain, whereas the benzylg roup interacts with the a 5 Phe187 side chain and the NH 1 and NH 10 protons are close to b 1 Tyr133 and Ser134r esidues, respectively.
The two binding modes can be used to interpret NMR results with MDA-MB-231c ells, suggesting that both the ligand arrangements in the binding pocket could contributet ot he experimental binding epitope. The possibility of adopting different binding modes within the a 5 b 1 receptor site, owing to the specific features of the pocket, could decrease the ligand ability to competew ith biotinylated fibronectin in the binding assay,t hus explainingt he low affinity for the isolated receptor.
Conclusions
In our current work, we planned to investigate the interaction of cyclic RGD-DKP peptidomimetic ligands 2-7 with a 5 b 1 integrin by exploiting an integrated computational and experi- 2017, 6,128 -136 www.chemistryopen.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim mental approach. Our ligands, designed to target the a v b 3 integrin, adopt an extended conformation of the RGD moiety, appropriate also to interactu sefully with the receptor site of a 5 b 1 integrin.W eu se NMR methodologies based on the Overhauser effect: STDa nd transferred NOESY, to study the ligandprotein interactions. The NMR experiments were performed on as uspension of intact MDA-MB-231b reast cancerc ells where the a 5 b 1 integrin is overexpressed,a llowing for ad etailed investigation of the binding process very close to physiological conditions. The NMR resultsw ere supported by docking calculations and were compared with competitive binding assays to the purified a 5 b 1 integrin.
The conformational analysiso ft he boundl igands revealed that the bioactive conformations of the ligands can be represented with two well-defined preferred geometries:t ype Ia nd type III. Remarkably,t he ligandsa dopting the type Ic onformation in the bound state (compounds 4, 6,a nd 7)s howedt he best binding affinities to the a 5 b 1 receptor.T he resultso btained from STD-NMR experiments are in agreement with docking analysis, pinpointing how the ligand stereochemistry and functionalization at the DKP nitrogen atoms are decisive in the formation of the ligand-protein complex. In any case, the aromatic moieties as well as the guanidinic protons are in contact with the receptor,a lthough with different STD percentages for each ligand.T he best ligand of our library is compound 7 [IC 50 = 25.7 AE 6.2 nm]t hat produced top-rankedb inding modes conserving all the key interactions described for the RGD peptides in the X-ray complexes. Nevertheless, mimic 7 exhibits ab inding affinity for a 5 b 1 about1 00 times lower than that for a v b 3 .T his behavior was observed fora ll compounds of the library and might be imputed to the features of the a 5 b 1 receptor site. In conclusion, the combination of advanced NMR techniques and computational modeling permitted us to identify structural requirements necessary to obtain an effective ligand.
Experimental Section Competitive BindingAssays
Purified recombinant human integrin a 5 b 1 (R&D Systems, Inc.,M inneapolis, MN, USA) was diluted to 0.5 mgmL À1 in coating buffer containing 20 mm Tris-HCl (pH 7.4), 150 mm NaCl, 1mm MnCl 2 , 2mm CaCl 2 ,a nd 1mm MgCl 2 .D iluted receptor (100 mL/well) was added to 96-well microtiter plates (NUNC MW 96F Maxisorp Straight) and incubated overnight at 4 8C. The plates were then incubated with blocking solution [coating buffer plus 1% bovine serum albumin (Sigma, St. Luis MO, USA)] for an additional 2h at room temperature to block nonspecific binding, followed by 3h incubation at room temperature with various concentrations (10 À12--10 À4 m)o ft est compounds in the presence of 1 mgmL À1 biotinylated fibronectin (Sigma, St. Luis MO, USA). Biotinylation was performed by using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing, the plates were incubated for 1h at room temperature with streptavidin-biotinylated hourseradish peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min incubation with 100 mL/well substrate reagent solution (R&D Systems, Minneapolis, MN, USA) before stopping the reaction by addition of 50 mL/well 2N H 2 SO 4 .T he absorbance at 415 nm was read in aS ynergyTM HT multi-detection microplate reader (BioTek Instruments, Inc.) . Each data point represents the average of triplicate wells;d ata analysis was carried out by nonlinear regression analysis with Prism GraphPad program.
Computational Studies
Protein Setup
Twoc rystal structures of the extracellular domain of the integrin a 5 b 1 in ac omplex with linear and cyclic RGD peptides (PDB code: 3VI4 and 4WK4, respectively) were used for docking studies. Docking was performed only on the globular head of the integrin, because the headgroup of integrin has been identified in the X-ray structure as the ligand-binding region. The two protein structures were set up for docking as follows:t he protein with the linear RGD ligand was truncated to residue sequences 40-351 for chain a (chain Ao fc rystal asymmetric unit) and 121-358 for chain b (chain Bo fc rystal asymmetric unit). All water was deleted. According to X-ray structures, metal cations at MIDAS have been modeled as Mg 2 + ions, whereas all the other metal cations were modeled as Ca 2 + ions. As the complex of integrin a 5 b 1 bound to the linear RGD peptide, that is, 3VI4.pdb, lacks the metal ion of AD-MIDAS (adjacent to MIDAS, metal ion-dependent adhesion site), it was added according to the apo structure of integrin (3VI3.pdb) and to the cyclic RGD peptide crystallographic complex (4WK4.pdb). The two structures were then prepared by using the Protein Preparation Wizard of the graphical user interface Maestro and the OPLSAA force field. Hydrogen bonds were optimized according to the exhaustive sampling option and the entire complexes were optimized by using ar estrained minimization with convergence on heavy atoms to aR MSD (root-mean-square deviation) of 0.30 .
LigandD ocking Calculations
The automated docking calculations were performed by using Glide version 5.7 in the standard precision (SP) mode. [14] The grids were generated for the RGD-integrin a 5 b 1 complexes structure prepared as described in the protein setup section. The center of the grid-enclosing box was defined by the center of the bound ligand. The enclosing box dimensions, which are automatically deduced from the ligand size, fit the entire active site. For the docking step, the size of the inner box for placing the ligand center was set to 12 .N of urther modifications were applied to the default settings. The GlideScore function was used to select 10 poses for each ligand. To validate the docking protocol, ah igh-affinity ligand was selected, that is, the cyclic pentapeptide Cilengitide 1a, showing an IC 50 value to isolated receptor of 14.4 nm (see Ta ble 1). The program was successful in reproducing the experimentally determined binding mode of RGD peptides, as it corresponds to the best-scored pose in both docking models (see Figure S1 ).
NMR Studies
All NMR spectra were registered at 283 and 298 Kb yu sing 7-9mm solutions of the test compounds in saline phosphate buffer (pH 7.2) and containing 10 %D 2 O. The NMR assignment of the compounds were performed through one-and two-dimensional STD-NMR spectra were acquired in the presence of about 10 6 MDA-MB-231 cells in at otal volume of 200 mL, using the watergate sequence for water suppression. The STD experiments discussed herein were achieved at 283 Kb yu sing at otal irradiation time of 2.94 s. All negative controls were performed:unwanted STD signals were not observed in any of the spectra.
